Hatefi A

ORCID: 0000-0003-4611-7469 · 1 paper in corpus · active 2024
2024
Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells.
Cancer cell international ·doi:10.1186/s12935-024-03469-0

BackgroundOlaparib is a PARP inhibitor inducing synthetic lethality in tumors with deficient homologous recombination (HRD) caused by BRCA1/2 mutations. The FDA has approved monotherapy for first-line platinum-sensitive, recurrent high-grad…